Renaissance Group LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 5.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 193,260 shares of the medical research company’s stock after buying an additional 9,415 shares during the period. Amgen makes up 1.2% of Renaissance Group LLC’s investment portfolio, making the stock its 26th largest position. Renaissance Group LLC’s holdings in Amgen were worth $31,708,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of AMGN. Alpha Omega Wealth Management LLC boosted its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. Thomas J. Herzfeld Advisors Inc. bought a new stake in shares of Amgen during the fourth quarter worth $102,000. Signature Estate & Investment Advisors LLC boosted its stake in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock worth $130,000 after buying an additional 95 shares during the period. Finally, Focused Wealth Management Inc boosted its stake in shares of Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock worth $127,000 after buying an additional 620 shares during the period. Hedge funds and other institutional investors own 79.12% of the company’s stock.
Amgen Inc. (AMGN) traded down 0.31% during midday trading on Friday, reaching $167.29. The company’s stock had a trading volume of 1,741,936 shares. The firm’s 50-day moving average price is $174.04 and its 200-day moving average price is $168.05. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21. The stock has a market capitalization of $122.07 billion, a PE ratio of 15.24 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the company posted $2.84 EPS. On average, analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be given a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.75%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is currently 41.93%.
WARNING: “Amgen Inc. (AMGN) Shares Bought by Renaissance Group LLC” was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/20/renaissance-group-llc-has-31-71-million-stake-in-amgen-inc-amgn-updated-updated-updated.html.
AMGN has been the subject of a number of research analyst reports. Sanford C. Bernstein reiterated a “market perform” rating and issued a $178.00 price target on shares of Amgen in a research note on Tuesday, April 25th. Cowen and Company reiterated a “buy” rating and issued a $209.00 price target on shares of Amgen in a research note on Thursday, April 27th. Robert W. Baird reiterated a “neutral” rating and issued a $165.00 price target on shares of Amgen in a research note on Friday, April 28th. Mizuho set a $195.00 price target on Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $189.00 price objective on Amgen and gave the company a “buy” rating in a report on Tuesday, May 9th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.